Evidence mapPaperPMID 41234538Full record

ReviewFrontiers in molecular biosciences2025

Molecular mechanisms and computational insights into human SGLTs: advancing toward selective SGLT1 inhibition.

Nadhiri Kaijage, Sebastian Kraszewski

Abstract readReview
In one paragraph

Review in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nadhiri Kaijage *Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, Wroclaw, Poland.
Sebastian Kraszewski *Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, Wroclaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sodium and glucose transporters (SGLTs) are integral membrane proteins crucial for glucose homeostasis, with SGLT1 and SGLT2 being widely studied as primary therapeutic targets. Despite SGLT2 inhibitors having been well clinically established, selective SGLT1 inhibition remains an unmet goal, although its potential in managing diabetes, cardiovascular disease, and cancer. Recent advances in structural biology, including cryo-electron microscopy and computational modeling approaches, have provided significant avenues into the molecular mechanisms of SGLTs and their inhibition. High-resolution structural data now reveal inhibitor binding modes and conformational dynamics, while molecular dynamics simulations, free energy calculations, and AlphaFold2 predictions further explain sodium coupling and conformational transitions. Notable differences between SGLT1 and SGLT2 include selectivity determinants,

Indexed as

cryo-electron microscopy (cryo-EM)glucose transport mechanismsmolecular dynamics simulationsselective SGLT1 inhibitionsodium-glucose cotransporter 1 (SGLT1)sodium-glucose cotransporter 2 (SGLT2)

Identifiers

PMID41234538
PMCPMC12605011

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.